| Literature DB >> 32729550 |
Jaysingh Singh1, Marika-Foteni Antimisiaris1.
Abstract
Epidiolex® (cannabidiol, aka CBD) is a recently approved FDA prescription drug for the treatment of epilepsy associated with Lennox-Gastaut and Dravet syndromes, and is increasingly used for treatment-resistant epilepsy. Rash was rarely reported in Epidiolex® clinical trial data. We report a case of Epidiolex®-related skin rash that developed in a delayed fashion in a 23-year-old female with medically refractory epilepsy. We also review the potential mechanism of Epidiolex®-related skin rash.Entities:
Keywords: CBD; Epidiolex; Epidiolex® (cannabidiol); antiepileptics; cannabinoid; drug interaction; hypersensitivity reaction; rash; skin
Mesh：
Substances：
Year: 2020 PMID： 32729550 DOI： 10.1684/epd.2020.1189
Source DB: PubMed Journal: Epileptic Disord ISSN： 1294-9361 Impact factor: 1.819